IMMUNOLOGY2024™: Day 4

Dr. Kristin Anderson, a leading expert in tumor-infiltrating lymphocyte therapy, returns to discuss groundbreaking advances in immunotherapy. She highlights a successful phase two trial for metastatic melanoma that achieved a remarkable 31% response rate. The conversation also explores innovative strategies like the integration of PD-1 inhibitors and vaccine-prime approaches to enhance treatment effectiveness. Additionally, they touch on how nutrient availability and hormonal impacts affect T cell function, shedding light on new avenues for tackling autoimmune diseases.